Optimizing RNA manufacturing for rapid RNA therapeutics development

In this webinar, Dr. Fengmei Pi, head of RNA Biology at GenScript’s Innovation Center will discuss key topics related to RNA therapeutics, optimization of mRNA stability and functionality, and the potentials of circular RNA as a novel class of therapeutics. She will also present an optimal in-vitro transcription (IVT) manufacturing workflow for high-performing mRNA production, and address stability and functionality concerns.

Furthermore, Dr. Pi will explore the unique features and advantages of circRNAs as a novel class of therapeutics, and the potential of circRNA to overcome the short half-life limitation of linear mRNA, opening new possibilities for RNA-based therapies.

Key learning objectives

• Gain insight into the limitations and bottlenecks faced in the field of RNA therapeutics, specifically related to the stability and functionality of mRNA molecules
• Learn about an optimized IVT manufacturing workflow that addresses the concerns of mRNA manufacturing
• Discover the unique properties of circRNA and how this technology can further enhance stability and longevity compared to linear mRNA

Who should attend?

• Small to large biopharma interested/working on RNA platforms, using mRNA/circularRNA as tools in downstream applications such as: mRNA therapeutics, protein replacement, cancer vaccines applications, and gene editing applications.
• Academics and researchers working in RNA field, new platform or protein expression groups, and cancer vaccine programs.
• LNP vendors who are looking for collaboration opportunities with mRNA service providers.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.